tiprankstipranks
PTC Therapeutics (PTCT)
NASDAQ:PTCT
Holding PTCT?
Track your performance easily

PTC Therapeutics (PTCT) Ownership - Who Owns PTC Therapeutics?

330 Followers

PTC Therapeutics (PTCT) Ownership Overview

1.15%29.94%38.69%17.25%12.97%
38.69% Other Institutional Investors
17.25% ETFs
12.97% Public Companies and
Individual Investors
The ownership structure of PTC Therapeutics (PTCT) stock is a mix of institutional, retail, and individual investors. Approximately 85.88% of the company’s stock is owned by Institutional Investors, 1.15% is owned by Insiders, and 12.97% is owned by Public Companies and Individual Investors.
The ownership structure of {name} ({ticker}) stock is a mix of institutional, retail, and individual investors. {displayInstitutionalData, select, display {Approximately {institutionalPercentage} of the company’s stock is owned by Institutional Investors} other {}}{displayInsiderText, select, display {, {insidersPercentage} is owned by Insiders} other {}}{displayInvestorsText, select, display {, and {retailInvestorsPercentage} is owned by Public Companies and Individual Investors.} other {}}

Recent Insider Trading Activity

Date
Name
Activity
Value
Jul 18, 2024
xxxxxxxxxxxxx
$77191
May 24, 2024
xxxxxxxxxxxxx
$764800
May 08, 2024
Lee Scott Golden
Evp & Chief Medical Officer
xxxxxxxxxxxxx
$5744
Apr 22, 2024
Matthew B. Klein
Ceo,director
xxxxxxxxxxxxx
$83655

Recent Hedge Fund Trading Activity

Date
Firm
Activity
Value
Sep 30, 2024
xxxxxxxxxxxxx
$327815

Top Shareholders

Holder
# of Shares
Type
% Holding
Value
7,265,482Institution9.42%311,616,523
6,556,813Institution8.50%281,221,710
4,168,888Institution5.41%178,803,606
3,727,531Institution4.83%159,873,805
1,800,499Institution2.33%77,223,402
1,382,679Institution1.79%59,303,102
1,205,904Institution1.56%51,721,223
1,095,290Institution1.42%46,976,988
874,188Institution1.13%37,493,923
855,911Institution1.11%36,710,023

Top Mutual Fund Holders

Holder
# of Shares
Type
% Holding
Value
6,556,813Institution8.50%281,221,710
4,168,888Institution5.41%178,803,606
1,800,499Institution2.33%77,223,402
1,382,679Institution1.79%59,303,102
874,188Institution1.13%37,493,923
855,911Institution1.11%36,710,023
852,706Institution1.11%36,572,560
823,985Institution1.07%35,340,717
808,269Institution1.05%34,666,657
540,788Institution0.70%23,194,397

Top ETF Holders

Holder
# of Shares
Type
% Holding
Value
2,401,636Institution3.11%95,873,309
2,067,250Institution2.68%88,664,353
1,928,131Institution2.50%76,970,990
1,147,509Institution1.49%45,808,559
1,076,045Institution1.40%45,150,848
1,059,853Institution1.37%42,309,332
520,142Institution0.67%22,308,890
518,708Institution0.67%22,247,386
372,107Institution0.48%15,613,610
347,072Institution0.45%13,855,114

FAQ

Who Owns PTC Therapeutics (PTCT)?
According to the latest TipRanks data, approximately 38.69% of the company's stock is held by institutional investors, 1.15% is held by insiders, and 12.97% is held by retail investors.
    What percentage of PTC Therapeutics (PTCT) stock is held by institutional investors?
    According to the latest TipRanks data, approximately 38.69% of PTC Therapeutics (PTCT) stock is held by institutional investors.
      What percentage of PTC Therapeutics (PTCT) stock is held by retail investors?
      According to the latest TipRanks data, approximately 12.97% of PTC Therapeutics (PTCT) stock is held by retail investors.
        Who owns the most shares of PTC Therapeutics (PTCT)?
        Vanguard owns the most shares of PTC Therapeutics (PTCT).
          What is the significance of the ownership structure for a publicly traded company?
          The ownership structure can impact the company's decision making, as large institutional investors may exert influence on the company's management and can also affect the company's stock price with their buying and selling patterns.
            What am I Missing?
            Make informed decisions based on Top Analysts' activity
            Know what industry insiders are buying
            Get actionable alerts from top Wall Street Analysts
            Find out before anyone else which stock is going to shoot up
            Get powerful stock screeners & detailed portfolio analysis